Understanding Fibromyalgia: Beyond the Myths
Fibromyalgia: A Pain Medicine Consultant’s Perspective on a Complex and Contested Diagnosis
Fibromyalgia affects millions of people, yet it remains one of the most misunderstood chronic pain conditions. Many patients arrive in clinic feeling dismissed, confused, or oversimplified by the label — and that frustration is valid. This article shares an honest, evidence-informed perspective on what fibromyalgia is, what it is not, what we understand about the biology, and how it can be approached more effectively in specialist practice.
Key points
- Fibromyalgia is real, but it is a syndrome, not a single disease.
- Normal blood tests and scans are expected, because the problem is how the nervous system processes pain, not visible tissue damage.
- Other pain conditions can exist alongside fibromyalgia, and they should not be missed.
- Treatment works best when it is layered: education, movement, sleep, psychological support, and targeted interventions where appropriate.
- Many patients improve meaningfully over time with the right combination of understanding, support, and treatment.
Neural pathways and neurotransmitters
Fibromyalgia is not a single disease — and never has been
Fibromyalgia is often spoken about as if it were one clearly defined medical condition. In reality, it has always been a syndrome — a collection of symptoms that tend to occur together — rather than a disease with a single cause, single mechanism, or single treatment.
Over decades, the concept evolved from tender point syndromes toward broader criteria recognising widespread pain, fatigue, poor sleep, and sensory sensitivity. This helped many patients gain recognition and validation, but it also created a highly heterogeneous group of people carrying the same label despite different drivers of pain.
Experiencing fibromyalgia does not mean you are weak, imagining symptoms, or “failing” to cope. It reflects real changes in how the nervous system processes signals — but those changes can arise for different reasons in different people.
The biology of fibromyalgia: what we know (and what we don’t)
Signpost: A useful way to think about fibromyalgia is that the nervous system becomes over-sensitive to “danger” signals, amplifying pain, fatigue, and sensory symptoms.
Central sensitisation — beyond the buzzword
Central sensitisation means the nervous system has become over-responsive. Signals that would normally be filtered, dampened, or ignored can be amplified instead, so that pain spreads, fluctuates, and persists even when there is no ongoing tissue injury.
- Increased excitability of pain-processing neurons in the spinal cord
- Reduced inhibitory (“calming”) signals from the brain
- Altered brain processing in regions involved in pain, emotion, and attention
This is a physiological process, not a psychological explanation.
Peripheral contributors: the dorsal root ganglia (DRG)
Signpost: Fibromyalgia is not purely “central”. Nerves outside the spine can become overactive and keep pushing pain signals into the system.
Emerging research highlights the role of the dorsal root ganglia — clusters of sensory nerve cell bodies just outside the spinal cord. These structures are biologically active and can amplify incoming signals. If DRG neurons become hyperexcitable, they may provide persistent abnormal input that helps drive and maintain central sensitisation.
This model helps explain widespread tenderness, unpredictable flares, and why some patients gain partial benefit when focal peripheral pain drivers are treated.
Neuro-immune signalling
Research also suggests altered communication between the immune and nervous systems. This is not classic inflammation (which is why standard inflammatory markers are usually normal). Instead, studies describe differences in immune signalling molecules (cytokines) and immune-like activity within the nervous system that may influence pain sensitivity, fatigue, and sensory hypersensitivity. Important uncertainties remain, but the overall picture supports dysregulated signalling rather than tissue damage.
Why blood tests and scans are normal — and why that is expected
One of the most distressing experiences for patients is being told that tests are “normal”. Blood tests are designed to detect inflammation, infection, autoimmune disease, or organ dysfunction. Imaging shows structure. Fibromyalgia does not primarily involve inflammation or structural damage, so normal results are expected.
This does not mean “nothing is wrong”. It means the problem lies in function rather than structure — in how pain signals are processed, amplified, and regulated.
Clinical principle: Normal tests should support careful diagnosis and reassurance, not dismissal.
Fibromyalgia vs inflammatory causes of widespread pain
| Feature | Fibromyalgia | Inflammatory conditions (e.g. inflammatory arthritis) |
|---|---|---|
| Primary driver | Altered pain processing / sensitisation | Inflammation in joints/tissues |
| Blood tests | Usually normal inflammatory markers | Often raised ESR/CRP and/or other markers |
| Imaging | Often normal or incidental age-related findings | May show synovitis/erosions/inflammatory change |
| Morning stiffness | Common but variable | Often prominent and prolonged |
| Fatigue / sleep disturbance | Very common and often severe | May occur but often secondary |
| Response to anti-inflammatories | Limited or inconsistent | Often clearer benefit |
Note: Patients can have fibromyalgia alongside inflammatory or mechanical pain conditions. One diagnosis does not exclude another.
Invalidation: the “second pain” of fibromyalgia
Many patients experience a second burden beyond physical symptoms: disbelief, minimisation, or being told “nothing is wrong”. Invalidation worsens distress and can amplify symptoms by increasing threat, uncertainty, and hypervigilance.
At Pain Spa, we begin by listening fully and taking symptoms seriously. Validation is not indulgence — it is the foundation of effective care.
Overdiagnosis and missed pathology: why fibromyalgia must never end assessment
Fibromyalgia is a valid diagnosis — but only after careful assessment. Problems arise when it becomes a diagnostic shortcut, applied quickly to explain widespread pain without considering treatable contributors or alternative conditions.
Equally, under-recognition is harmful when patients are dismissed or repeatedly reassured that “nothing is wrong”. Both extremes damage trust and delay effective care.
Clinical principle: Fibromyalgia does not exclude other diagnoses, and it should never stop diagnostic thinking.
Differential diagnosis done properly
Differentiating fibromyalgia from other causes of widespread pain requires clinical reasoning rather than reliance on a single test. Inflammatory conditions often produce objective markers and prolonged morning stiffness. Mechanical pain often relates to posture, movement, or load. Neuropathic pain follows nerve distributions and sensory changes.
Fibromyalgia tends to feature widespread pain sensitivity with fatigue, poor sleep, and fluctuating symptoms without structural or inflammatory explanations. Overlap is common, and rigid categorisation is rarely helpful.
In practice, we remain alert for treatable contributors that may coexist with fibromyalgia, such as facet or sacroiliac joint pain, myofascial pain, and nerve-related pain.
The fibromyalgia blood test (FM/a): what it does — and what it doesn’t
You may come across claims about a blood test called the FM/a test that can “diagnose” fibromyalgia. This test does not look for inflammation, autoimmunity, infection, or tissue damage.
Instead, it examines how certain immune cells behave in vitro — meaning outside the body, in the laboratory. Immune cells taken from a blood sample are stimulated, and the test measures the release of signalling proteins called cytokines, which are involved in pain sensitivity and fatigue. These measurements are combined into a composite score.
What the FM/a test detects are differences in immune response patterns seen on average across groups of people diagnosed with fibromyalgia, rather than a reliable marker of disease in an individual. These patterns reflect altered immune–nervous system signalling, not active inflammation.
Importantly, the FM/a test is not sufficiently accurate for individual diagnosis, is not recommended by current clinical guidelines, and does not change clinical management. Fibromyalgia therefore remains a clinical diagnosis based on symptoms and careful assessment.
Treatment: layered, individualised, and realistic
Non-pharmacological foundations: The strongest evidence supports education that makes sense of pain mechanisms, graded and individualised exercise, sleep optimisation, and pacing strategies that avoid boom-and-bust cycles. Psychological therapies can help when framed appropriately — as tools to reduce the impact of chronic pain on function and quality of life, not as proof that pain is imagined.
Targeted treatment of peripheral contributors: When focal pain generators are present, treating them can reduce ongoing peripheral input and help calm the overall pain system. Examples include trigger point injections for myofascial pain or joint/nerve-targeted interventions when clinically indicated.
Medications: Medicines may help modestly, particularly with sleep or flare-ups, but they rarely transform the condition on their own. Opioids are not recommended because they do not address central sensitisation and may worsen pain over time while carrying significant risks.
GP summary
Fibromyalgia is a clinical syndrome of altered pain processing with typically normal inflammatory markers and imaging; it may coexist with treatable peripheral pain generators and other pathology.
Management is layered (education, graded activity, sleep, psychological strategies, and targeted interventions where appropriate); opioids are not recommended, and the FM/a blood test (in-vitro cytokine response assay) is not guideline-endorsed and does not alter routine management.
Central Sensitisation and Amplified Pain Processing
The Pain Spa approach
At Pain Spa, fibromyalgia is never treated as a “diagnosis of exclusion” or a reason to stop investigating. We recognise fibromyalgia as real and complex, and we remain alert to treatable contributors that can coexist with it.
- Careful assessment for treatable pain generators (e.g., sacroiliac joint dysfunction, facet-mediated pain, myofascial trigger points, nerve-related pain)
- Targeted interventions when likely to reduce a clear peripheral driver
- Rehabilitation strategies that respect sensitisation (graded movement, pacing, sleep optimisation)
- Clear, realistic goal-setting focused on function and quality of life
Dr Krishna has extensive experience managing complex pain presentations, combining evidence-based education, rehabilitation, and targeted interventions where appropriate.
Final synthesis
Fibromyalgia is real, but it is not simple. Normal tests are expected. The label should never end assessment, and meaningful improvement is possible when care is thoughtful, individualised, and layered.
Call to action: If you have been diagnosed with fibromyalgia and would like a thorough, individualised assessment — including exploring treatable contributors and targeted options — you can contact Pain Spa at clinic@painspa.co.uk or via our website www.painspa.co.uk. to arrange a consultation.